SCHEMBL3377188

SCHEMBL3377188

O=C(NCc1ccccc1)c1cccc(C(=O)N2CCN(CC3CCCCC3)CC2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
TSHR P16473 1/20 0.54
MAPK1 P28482 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
NAMPT P43490 1/20 0.53
PARP1 P09874 1/20 0.51
HDAC2 Q92769 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
ALDH1A1 P00352 3/20 0.49
CNR1 P21554 1/20 0.49
PRKAA2 P54646 1/20 0.48
RAB9A P51151 2/20 0.48
PKM P14618 1/20 0.48
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3276251 0.90 NAMPT (0.59) LMNAMEN1KMT2ASMN1; SMN2NAMPT
SCHEMBL3377193 0.85 NAMPT (0.53) LMNAMEN1KMT2ATSHRMAPK1
SCHEMBL3276253 0.80 NAMPT (0.64) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3379826 0.79 KDM1A (0.56) LMNAMEN1KMT2ATSHRMAPK1
SCHEMBL3379271 0.78 MAPK1 (0.65) LMNAMEN1KMT2ATSHRMAPK1
SCHEMBL10293610 0.75 ALDH1A1 (0.69) LMNAMEN1KMT2ATSHRMAPK1
SCHEMBL3377135 0.74 ALDH1A1 (0.72) LMNAMEN1KMT2ATSHRMAPK1
SCHEMBL1786835 0.74 OPRM1 (0.54) LMNAMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL11900328 0.74 HDAC6 (0.87) MEN1KMT2ASMN1; SMN2HDAC2HDAC8
SCHEMBL12822505 0.73 PARP1 (0.60) PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 LMNA 1619/4885MEN1 608/4885KMT2A 386/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 LMNA 2145/4885MEN1 2747/4885KMT2A 1511/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 LMNA 1619/4885MEN1 608/4885KMT2A 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.